Targets › TSLP
5 programs from 5 companies in 34 trials: 13 Phase 3, 13 Phase 2, 7 Phase 1, 1 Phase 4; Respiratory, Other, Oncology; next expected readout Dec 2026.
[Isoform 1]: Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells..; FUNCTION: [Isoform 2]: May act as an antimicrobial peptide in the oral cavity and on the skin. (UniProt, Q969D9)
Open in Phaseline: the race on TSLP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQC2731 injection anti-TSLP monoclonal antibody; blocks TSLP signaling pathway and inhibits downstream cytok | TSLP | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Asthma; Chronic Obstructive Pulmonary Disease | Dec 2026 |
| Suzhou Suncadia Biopharmaceuticals | SHR-8068 Injection TSLP receptor antagonist | TSLP | Phase 3 | Advanced Biliary Tract Cancer; Advanced Hepatocellular Carcinoma; Advanced or Metastatic Non-small Cell Lung Cancer; Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma … | Dec 2026 |
| AstraZeneca | Tezepelumab Thymic stromal lymphopoietin inhibitor | TSLP | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps; Eosinophilic Esophagitis; Severe Asthma; Asthma … | Jan 2027 |
| Windward Bio | WIN378 TSLP ligand-blocking monoclonal antibody | TSLP | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease); Asthma | Dec 2027 |
| Shanghai Huaota Biopharmaceutical | HB0056 Bispecific antibody targeting TSLP and IL-11 | TSLP, IL11 | Phase 1 | Healthy; Asthma | Aug 2027 |
Asthma (4) Severe Asthma (3) Chronic Rhinosinusitis With Nasal Polyps (2) Chronic Obstructive Pulmonary Disease (COPD) (2) Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (1) Chronic Obstructive Pulmonary Disease (1) Advanced Biliary Tract Cancer (1) Advanced Hepatocellular Carcinoma (1) Advanced or Metastatic Non-small Cell Lung Cancer (1) Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma (1) Biliary Tract Cancer (1) Gastric Cancer (1)
small molecule (3), mixed (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.